BI-1265162 clinical trials
Also written BI 1265162.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses BI-1265162 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 1265162
- 3
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses BI-1265162 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the BloodCompletedPhase 1Boehringer IngelheimNCT03907280Written as BI 1265162 (T1)
- A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the BodyTerminatedPhase 1Boehringer IngelheimNCT04267276Written as Part 1: BI 1265162 - intravenous
- This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy MenCompletedPhase 1Boehringer IngelheimNCT03349723Written as BI 1265162
- This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.CompletedPhase 1Boehringer IngelheimNCT03576144Written as BI 1265162
- A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1TerminatedPhase 2Boehringer IngelheimNCT04059094Written as BI 1265162